Please assess the completion status of the following clinical trial:

Trial Title: Effect of Recombinant Human Growth Hormone (rhGH) on Abdominal Fat and Cardiovascular Risk in Obese Girls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescent girls 13-21 years old with bone age ≥ 14 years~* Overweight girls: Body Mass Index (BMI) greater than the 95th percentile for age~* Waist/Hip ratio ≥ 0.85~* Insulin Like Growth Factor -1 (IGF-1) below -0.5 standard deviations (SD) for pubertal stage or age~Exclusion Criteria:~* Pregnancy (positive pregnancy test) prior to enrollment in the study~* Significant weight gain or loss within 3 months of study (more than 5 kg)~* Use of medications that affect GH or cortisol levels (such as estrogen including oral contraceptive pills, oral glucocorticoids)~* Use of medications such as Meridian and Orlistat~* Presence of diabetes mellitus~* Uncontrolled Thyroid disorders~* Chronic renal insufficiency~* Participation in another simultaneous medical investigation or trial~* Active neoplasm or history of cancer~* Prader-Willi syndrome~* History of scoliosis if bone age is \<15 years~* Hypersensitivity to rhGH or constituents of the injections

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- recombinant human growth hormone (Type: EXPERIMENTAL): Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).